Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,820 result(s) found. Displaying page 75 of 141.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    EudraCT Number: 2019-001772-10 Sponsor Protocol Number: 2016-06 Start Date*: 2020-02-14
    Sponsor Name:Assistance Publique-Hôpitaux de Marseille
    Full Title: Phase I study of oral metronomic NAVELBINE® and HEMANGIOL®combination for children and teenagers with refractory/relapsing solid tumors
    Medical condition: Pediatric Solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004155-16 Sponsor Protocol Number: CAAA601A42101 Start Date*: 2022-06-07
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide ...
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002477-26 Sponsor Protocol Number: NVL-520-01 Start Date*: 2021-11-26
    Sponsor Name:Nuvalent, Inc.
    Full Title: A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)
    Medical condition: Advanced Non-Small Cell Lung Cancer (NSCLC)and Other Solid Tumors with ROS1+ rearrangement
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) DE (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002848-32 Sponsor Protocol Number: M-2017-322 Start Date*: 2018-05-15
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies.
    Medical condition: Pediatric and adult patients with relapsed/refractory (r/r) CD19-expressing B cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004883-23 Sponsor Protocol Number: APHP191116 Start Date*: 2020-10-06
    Sponsor Name:APHP
    Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adu...
    Medical condition: Adult patients (n=10) requiring an allogeneic HSCT for the treatment of AML with an unfavorable prognosis according to international criteria in first complete remission or second complete remissio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000172-38 Sponsor Protocol Number: NP137-CT-02 Start Date*: 2020-09-04
    Sponsor Name:NETRIS PHARMA
    Full Title: A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Ne...
    Medical condition: Locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001197 Adenocarcinoma of the cervix PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014987 Epidermoid carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000599-38 Sponsor Protocol Number: RC20_0007 Start Date*: 2020-11-26
    Sponsor Name:NANTES CHU
    Full Title: A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal trans...
    Medical condition: Kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004863 10051366 Kidney graft dysfunction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002814-38 Sponsor Protocol Number: 69HCL18-0857 Start Date*: 2019-12-09
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment
    Medical condition: Low-risk gestational trophoblastic neoplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10018211 Gestational trophoblastic tumor NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001614-16 Sponsor Protocol Number: 16TETE04 Start Date*: 2016-09-22
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma.
    Medical condition: Recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000509-29 Sponsor Protocol Number: GCT1042-02 Start Date*: 2022-11-04
    Sponsor Name:Genmab A/S
    Full Title: A Phase 1/2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
    Medical condition: Metastatic Solid Malignant tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002996-36 Sponsor Protocol Number: 15TETE04 Start Date*: 2021-06-23
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing som...
    Medical condition: Recurrent or refractory neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003579-31 Sponsor Protocol Number: N/2014/68 Start Date*: 2016-01-20
    Sponsor Name:Centre Hospitalier Régional Universitaire de Besançon
    Full Title: PHASE I/II DE RADIOCHIMIOTHERAPIE DANS LES CANCERS DE L’ŒSOPHAGE DU SUJET AGE. OSAGE
    Medical condition: Patient âgé de 75 ans et plus porteurs d'un cancer de l'oesophage non opérable et avec une maladie localisée
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004808-60 Sponsor Protocol Number: HD-CAR-1/V04 Start Date*: 2018-04-12
    Sponsor Name:University Hospital Heidelberg
    Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial
    Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    23.0 100000004864 10029595 Non-Hodgkin's lymphoma NOS refractory LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003215-63 Sponsor Protocol Number: 69HCL19_0032 Start Date*: 2020-03-10
    Sponsor Name:Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
    Full Title: Cultured Autologous Oral Mucosa Epithelial sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency - FEMJA for « Feuillet Epithélial de Muqueuse Jugale Autologue »
    Medical condition: Bilateral Limbal Stem Cell Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10072138 Limbal stem cell deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001385-35 Sponsor Protocol Number: EXS21546-002 Start Date*: 2022-11-25
    Sponsor Name:Exscientia AI Limited
    Full Title: A phase 1b/2a study to assess the safety, tolerability, pharmacokinetic and anti-tumoural activity of EXS21546 in combination with PD-1 inhibitor in patients with advanced solid tumours.
    Medical condition: Solid advanced tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001283-30 Sponsor Protocol Number: SPK-3006-101 Start Date*: 2020-06-16
    Sponsor Name:Spark Therapeutics
    Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease
    Medical condition: Pompe Disease (also known as glycogen storage disease type II)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002245-18 Sponsor Protocol Number: OMX-0407-101 Start Date*: 2022-11-14
    Sponsor Name:iOmx Therapeutics AG
    Full Title: A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase inhibitor in patients with previously treated unresectable solid tumours
    Medical condition: Previously treated unresectable solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003705-34 Sponsor Protocol Number: RDC-PDE6A-01 Start Date*: 2019-07-02
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: PIGMENT – PDE6A gene therapy for retinitis pigmentosa
    Medical condition: PDE6A-linked retinitis pigmentosa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003388-39 Sponsor Protocol Number: KDO_DC1311 Start Date*: 2015-03-26
    Sponsor Name:Masarykova univerzita
    Full Title: COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT OR PRIMARILY METASTATIC HIGH-RISK ...
    Medical condition: Progressive, recurrent or primarily metastatic high-risk malignities
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000609-10 Sponsor Protocol Number: 2020-01-GMF-1 Start Date*: 2021-07-06
    Sponsor Name:Center for Surgical Science
    Full Title: A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery A clinical safety and proof-of-con...
    Medical condition: A combination of GM-CSF and metronidazole/fosfomycin treatment for pouchitis in Ulcerative Colitis patients after ileal-pouch-anal anastomosis surgery given as an enema or spray in the pouch.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036463 Pouchitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 00:04:51 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA